Skip to main content
. 2020 May 28;20(2):1295–1299. doi: 10.3892/ol.2020.11678

Figure 1.

Figure 1.

Comparison of proliferation ability among groups. After 96 h, the proliferation ability of the RPMI-8226 cells treated with 20, 50 and 80 nmol/l bortezomib was lower compared with that of the control group. The proliferation abilities of the cells in the control group and those treated with 20 nmol/l bortezomib had no statistically significant difference (P>0.05); however, the proliferation ability was significantly higher than that of the cells treated with 50 and 80 nmol/l bortezomib (P<0.05). *P<0.05, compared with the cells treated with 20 nmol/l bortezomib.